Open AccessHepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions
Author(s) -
Ezequiel Ridruejo,
Matías J. Pereson,
Diego Martín Flichman,
Federico A. Di Lello
Publication year - 2021
Publication title -
world journal of hepatology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.913
H-Index - 55
ISSN - 1948-5182
DOI - 10.4254/wjh.v13.i9.1069
Subject(s) - medicine , context (archaeology) , drug resistance , hepatitis c virus , virology , virus , genetics , paleontology , biology
The hepatitis C virus has a high mutation capacity that leads to the emergence of resistance-associated substitutions (RAS). However, the consequence of resistance selection during new direct-acting antiviral drug (DAA) treatment is not necessarily the therapeutic failure. In fact, DAA treatment has shown a high rate (> 95%) of sustained virological response even when high baseline RAS prevalence has been reported. In the context of RAS emergence and high rates of sustained viral response, the clinical relevance of variants harboring RAS is still controversial. Therefore, in order to summarize the data available in international guidelines, we have reviewed the clinical utility of testing RAS in the era of new pangenotypic DAA drugs.